Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Company Overview
Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.
Business Model and Operations
At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:
- Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
- Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
- Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.
This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.
Market Position and Competitive Landscape
Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.
Product Portfolio and Therapeutic Solutions
The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:
- Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
- Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
- Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.
Research, Development, and Quality Assurance
The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.
Commitment to Scientific Integrity and Patient Care
Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.
Strategic Value Proposition
Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.
Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.
Harrow Health, Inc. (NASDAQ: HROW) has released its inaugural 2022 Corporate Transparency Report, emphasizing its commitment to making sight-saving medications accessible. CEO Mark L. Baum highlights sustainable business practices aimed at benefiting customers and communities. The report details the company’s dedication to innovation, quality, and ethical standards while maintaining strong corporate governance. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in affiliated companies. The report is available in the Investors section of the company’s website.
NASHVILLE, Tenn. -- Harrow Health (NASDAQ: HROW) announced participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations website starting January 10 at 7:00 a.m. ET, remaining accessible for 90 days. Harrow Health specializes in ophthalmic healthcare and operates ImprimisRx and Visionology, focusing on innovative eye care solutions.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.
Harrow Health, Inc. (NASDAQ: HROW) will release its third-quarter financial results for 2021 on
Harrow Health, Inc. (NASDAQ: HROW) announced a $13.5 million senior secured loan to Melt Pharmaceuticals, Inc. to support the Phase 2 study of its lead drug candidate MELT-300, aimed at providing a non-opioid solution for sedation during cataract surgery. Melt plans to dose the first patient in
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, announced that Mark L. Baum, CEO, and Andrew Boll, CFO, will participate in two virtual investor conferences. The first is the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021, where a pre-recorded presentation will be available on their website from 7:00 a.m. ET. The second is the Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference on September 15, 2021, where management will hold one-on-one meetings with investors.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
